Enable Biosciences, Lund University Report High-Performing Immunoassay for Type 1 Diabetes and Celiac Disease

Scientists at Enable Biosciences and Lund University published a report describing a multiplex assay for five autoantibodies associated with type 1 diabetes and celiac disease in the Journal of Immunological Methods.

Autoantibodies are highly predictive biomarkers of autoimmune diseases like type 1 diabetes and celiac disease. Clinical care for both conditions can be improved by early diagnosis with high-throughput and accurate assays, but current technologies limit the widespread application of screening services. The authors reported a five-plex assay based on Enable’s proprietary Antibody Detection by Agglutination PCR technology (ADAP) that simultaneously detects four T1D-associated autoantibodes (anti-insulin, anti-GAD, anti-IA2, and anti-ZnT8) and the primary autoantibody associated with celiac disease (anti-TTG) from only 4 microliters of serum. Critically, the ADAP assay showed improved analytical sensitivity when compared to the clinical gold standard assay for all analytes except anti-IA2.

“We’ve achieved a highly favorable set of characteristics for a clinical immunoassay. While some assays are sensitive, only require low sample volumes, automated, multiplexable, and high-throughput, we believe that this new assay is the only one that combines all these attributes into a single platform.” said Jason Tsai, PhD, CTO of Enable Biosciences and a senior author of the article.

The article can be found online from the Journal of Immunological Methods: https://www.sciencedirect.com/science/article/pii/S0022175922000527